Prelude Therapeutics Incorporat
PRLD
Last
$3.89
Day
+0.3%
1y
+177.1%
5y
-87.7%
52w
-43.2%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1131d
EMA 21
4.20
EMA 50
4.55
EMA 200
3.95
20d high
-21.0%
5y high
-88.2%
5y range
10th
Positions held
Your positionsPRLD isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
1
Hold
watch
Signal
Neutral
Target
$4.40
Stop
$3.45
Stop distance
11.3%
Target vs last
+13.1%
Fundamentals
| Market cap | $309.64M | Enterprise value | $265.51M | Trailing P/E | — | Forward P/E | -7.05 |
| PEG | — | Price / book | 2.99 | Beta | 0.96 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 100.0% | Operating margin | -2.7% |
| Profit margin | -2.7% | ROE | -57.7% | ROA | -27.2% | Debt / equity | 0.13 |
| Current ratio | 4.07 | Free cash flow | -$13.84M | Analyst recommendation | strong_buy | Mean target | $9.20 |
| 52w high | $6.83 | 52w low | $1.15 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $5.7M | $4.6M | $5.6M | $6.5M | $0.0M | — |
| Op margin | -270.9% | -309.5% | -307.6% | -314.1% | — | — |
| Net income | -$13.9M | -$10.4M | -$16.5M | -$19.7M | -$31.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$15.5M | -$14.2M | -$17.3M | -$20.4M | -$32.2M | — |
- Revenue +25% vs prior quarter ($5.7M vs $4.6M).
- Operating margin expanded to -270.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $12.1M | $7.0M | $0.0M | $0.0M |
| Op margin | -861.3% | -1995.9% | — | — |
| Net income | -$99.5M | -$127M | -$122M | -$115M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$105M | -$140M | -$132M | -$124M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-11 · Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 · Prelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug Trial
2026-07-31 · Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
2026-07-17 · Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
Price (daily)
Full chart · RSI · MACD · patternsPRLD · daily-20.0% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin